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Background: A 35 country European cystic fibrosis (CF) demographic registry was developed to compare outcomes (EuroCareCF EC-FP6).
Methods: We applied methods that had successfully created country-specific registries inviting wide participation to obtain consent and collate
demographic and CFTR genotype data.
Results: Among 29,095 patients, a widely different country-specific prevalence of childhood CF exists that cannot be explained by differential
population frequency of mutant-CFTR or case under-ascertainment with a significant paucity of the homozygous p.Phe508del genotype that
presents in childhood in N90% of cases.
Conclusions: Excess premature childhood CF mortality may still occur. The better resourced Western Europe now has a ~5% mortality for
childhood CF, which is not apparent in many of the European countries reported here. In addition, a female survival disadvantage exists. The
reasons require further investigation. We showcase the value of simple data collection in one rare disease, which might interest those managing
rare diseases across the globe.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Database; Rare disease; Geography; Chronic disease; Genetics; p.Phe508del; CFTR
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Cystic fibrosis (CF) is one of the most common life-
shortening, recessively inherited rare diseases; it is most
prevalent in Europe, North America and Australasia [1,2].
The vast majority of CF-affected children present to health care
services within the first two years of life, many with severe life-
threatening disease affecting multiple organs (principally, lung,
bowel and the pancreas). CF occurs mainly in children of
European descent, while it is much rarer in the Eastern Asia and
in most of Africa, except in the European-derived populations
of Southern Africa [3]. Less frequently, CF occurs in Arabian
populations and throughout South East Asia where it is now
sufficiently common to necessitate the formation of specialist
CF Centre care. For example, such specialist CF clinics are now
found in parts of the Indian Subcontinent [4]. In urban settings,
as non-European population admixture increases across Europe
and North America, the underlying genetics of CF inheritance is
fast becoming a complex issue since the types of CF-causing
mutations differ from those found in original European
populations [5]. This is especially problematic for “two tier”
neonatal screening programmes, which are increasingly being
implemented worldwide [6].
1.1. Survival
Historically, and irrespective of geography or a country's
economic wealth, most CF-affected babies born in the mid last
century would have had very little chance of surviving into
adulthood since there were no effective therapies [1]. For
example, fifty years ago, around 90% of such infants died from
persistent diarrhoea and chronic malnutrition, typically before
their second birthday due to pancreatic failure [1]. Survival into
early childhood changed dramatically in the middle of the 1980s
[7] initially as a result of the development of potent and
relatively affordable acid-resistant pancreatic enzyme replace-
ment therapies that aided digestion of foodstuffs to compensate
for the pancreatic insufficiency that takes place during in utero
development. As a result of the development of paediatric CF
centres and their care teams, in subsequent decades, CF
prevalence among young adults began to accelerate such that
a CF patient born in the last two decades of the twentieth
century (in an economically developed nation) is now expected
to have a greater than 50% chance of living until they are about
40 years of age [8].
1.1.1. Survival from childhood onset
This transition has necessitated the development of adult-
oriented CF centres, no longer run by paediatricians for the most
part, but this practice varies across nations depending on the
availability of specialised adult CF care. Consequently, in some
countries paediatricians continue to look after CF adults.
Although survival of CF patients diagnosed in early childhood
is improving all the time, CF “survivors” into adulthood (rather
than those who often present in adulthood with a relatively milder
form of the disease without pancreatic failure), remain in a small
minority when compared to the entire demographic profile of allCF cases in a given population [9]. We recognised that adult
survivors of childhood CF do vary in prevalence across CF
centres with some well resourced and long standing adult CF
centres in Western Europe reporting a much higher prevalence of
such survivors of childhood onset disease [10]. At the outset of the
work reported here, we considered that in some countries without
the resources available to economically advanced nations, a
relative paucity of adult survivors from a CF diagnosis in infancy
could be reflective of an underlying higher mortality from an
earlier era in such ‘child-diagnosed’ cohorts. Hence, in this paper
we investigated the underlying CF demography focussing on
country-specific CF prevalence. Typically, CF survival improves
relatively slowly by approximately five years in each successive
ten year cohort [7,11,12] and it remains to be seen whether this
incremental trend will eventually flatten. It is estimated that the
annual mortality in current cohorts aged over 40 years is around
3–4% [9]. Such epidemiological predictions are generally robust
since they are largely based on data that meet stringent quality
criteria [13]. However, such accurate predictions result from
considerable and long-term investment, mainly by CF patient
support groups, that set up accurate, verified longitudinal
repositories of clinical and demographic data (i.e. CF Registries).
1.2. Registries
Currently, most CF Registries that report data are located in
Western Europe, North America and Australia. Their analyses
of the underlying demographic trends suggest that substantial
progress is being made in improving survival for almost all CF-
affected babies, with the caveat that this advance is
only reported from socio-economically developed nations
who have the necessary reporting structures in place. Investi-
gators examining the UK socialised medicine programme
(National Health Service, NHS) pioneered a critical example
of such a robust epidemiological approach [7]. The authors
provided evidence that multiple case ascertainment from the
subset of NHS hospitals caring for CF patients coupled to data
from Primary (Family) Care, the UK CF Trust (the CF patient
support organisation) and a comprehensive analysis of
Government recorded CF deaths (UK Registrars General)
confidently ascertains ~90% of the CF cases of all types
and severity referenced against the expected genetic incidence.
This comprehensive ‘UK Survey’ is no longer operational
and such highly accurate methodology cannot easily be
replicated in the vast majority of European countries that do
not have such an overarching government led infrastructure in
health care [5]. Mostly with respect to CF registries, the
fragmented nature of country-specific reporting leads to a
substantially lower coverage with typical estimates being
between 40% and 80%. Such coverage estimates mainly
rely on CF centre based aggregates of patient data composed
into a national or regional picture as described in detail
elsewhere [5,14,15]. In summary, registry evolution shows
that there is always a delicate balancing act between
collecting purely demographic information (small numbers of
highly accurate quantitative data fields, with a large population
coverage) versus the clinical imperative to be comprehensive
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high quality) both of which can, however, only be gathered
from CF centres with the necessary resources.
1.3. European expansion in 2004
At the outset, we recognised that it might be difficult to apply
CF centre-based methods across the whole of Europe given the
different country-specific trajectories of underlying economic
and health care infrastructure development. Such disparities in
development of care are highly relevant to CF since over the last
four decades its therapy has changed the most. In parallel with
the rapid positive socio-economic changes in Central and
Eastern Europe (since 1990) and following the expansion of the
European Union (EU) (May 2004) with “New Member States”,
the current paper reports cross-sectional CF demography, by
focussing on recent country-specific population profiles
aggregated from CF referral centres across 35 European
countries. Such was the demand from nations across Europe
to join our project that our original plan to collect data from 22
countries was soon surpassed and in the final event, we had to
turn away some countries because they arrived too late to meet
the tight deadlines of this time-limited European Commission
(EC) “Coordination Action” project which closed in June 2009.
1.4. EuroCareCF remit
This three year project was funded by the Sixth Framework
Programme under the eponymous name of EuroCareCF (www.
eurocarecf.eu; Project coordinator: D.N. Sheppard, University
of Bristol, Bristol, UK). The project was divided into ‘Work-
packages’ each dedicated to different tasks. The hypothesis
tested in our Workpackage 2 (relying on the coordinating efforts
of the Dundee and Prague groups) was contingent on the notion
that provision of simple oral therapeutic measures, such as acid-
resistant pancreatic enzyme replacement therapy from the
middle of the nineteen eighties, which had previously been
shown to correlate with a substantially improved survival
towards the end of the last century, would have a measurable
effect on disease outcome. Thus, we hypothesised that a current
cross-sectional snapshot of CF population profiles could
indicate how a given country's health care system was able to
deliver ‘at the bed side’ for this particularly vulnerable group of
CF children, who would otherwise suffer high mortality within
a few years after birth without appropriately targeted and
relatively affordable CF therapy. Our initial remit was to create
the conditions for legal consent. Using these procedures, which
took two years to develop and implement, we were contracted to
produce a report on country-specific CF demographics based on
the above consent that was compatible with the laws of each
country. Other Workpackages of the EuroCareCF project such
as Workpackage 1 focussed on care issues, care teams and their
underlying support structures. These issues are excluded from
the current report as they lay outside our remit. Here, we report
substantial variability in CF demography in some, but not all
countries that requires follow up from respective Health
Authorities both at EU and/or Member State levels. Ourfindings, when considered with those of other EuroCareCF
Workpackages might also be of interest to developing nations
where CF is increasingly being recognised as a clinical entity as
childhood mortality from infectious disease wanes and health
care resources increase.
2. Methods
2.1. Data collection
The methodological approach was based on pilot experi-
ence as detailed elsewhere [14]. As explained above, there
always exists a delicate balancing act between obtaining data
of high accuracy (i.e. only collecting limited data fields)
versus a justified desire to be as comprehensive as possible by
collecting additional clinical outcome data. In our earlier pilot
studies, we had already published on the possibility of
comparing clinical outcomes across continents from existing
data sets that had been already collated in developed nations in
their own CF Registries [5]. However, we found that this was
not a simple task because of the difficulties associated with the
separate country-specific development of standards and
definitions of disease complications. The principal problem
was in the lack of agreed international standards, even for
‘core’ clinical CF data, which would inevitably fail normative
criteria for clinical data quality [13] within any eventual report
that we might produce. For example, should we record best or
worst lung function and if we chose one or other option, could
we agree a ‘best’ reference equation? These standards were not
available and had not been internationally agreed upon.
Therefore, we chose the only other path available to us and
collected a focussed, quantitative data set containing a few,
high quality, verifiable fields mainly of a demographic nature
and related to the underlying CF genetics.
Our study design was underpinned by the fact that the
variation in CF prevalence between European populations had
already been previously assessed by a variety of methods
[3,16] providing evidence that the mean prevalence of CF in
Europe is 0.737/10,000, close to the value in the United States
(0.797/10,000), with the only outlier being the Republic of
Ireland where as many as 1 in 17 carry a defective CFTR.
Moreover, the random nature of CF incidence in the offspring
of apparently healthy (“obligate carrier”) parents of this
autosomal recessive “rare disease” from all social strata
provided additional confidence that the above approach was
justified. We had the further advantage that the background
data on the distribution of the most common CF-causing
mutations have been collected for many years from a
representative set of European molecular genetic diagnostic
laboratories which are traditionally affiliated to their respec-
tive CF centres. The size and quality of such data sets relies on
the stability of the Hardy–Weinberg equilibrium to estimate
the population prevalence of the defective CFTR gene [3].
Although the commonest p.Phe508del (synonymous with
ΔF508, Phe508del and F508del in “legacy nomenclature”)
mutation frequency decreases in Europe along the Northwest-
to-Southwest gradient, this mutation is “complemented” by
Table 1
Data include those patients who have died. Where fewer than 70 patients were
reported, the exact number has not been shown in order to maintain patient
anonymity as specified in the consents and ensure compliance with the Data
Protection Directive 95/46/EC of the European Parliament and country-specific
national legislation (data not shown).
Country Youngest patient born Patients reported
Armenia 2006 b70
Austria 2006 94
Belarus 2007 153
Belgium 2005 912
Bosnia 2007 b70
Bulgaria 2007 75
Croatia 2007 106
Cyprus 2006 b70
Czech Republic 2007 490
Denmark 2005 441
Estonia 2004 b70
France 2004 4533
Georgia 2008 73
Germany 2005 4758
Greece 2007 177
Hungary 2006 113
Iceland 2005 b70
Ireland 2006 675
Israel 2005 498
Italy 2003 4138
Latvia 2006 b70
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pancreatic insufficiency (PI) in a similar manner to p.
Phe508del. Therefore, the distribution of PI-inducing geno-
types of CF-causing mutations is not generally different in
various European populations since historically carriers of
these alleles were positively selected for, as has been the case
for p.Phe508del. Moreover, CF carrier and/or neonatal
screening programmes are gradually providing updated and
more accurate CF incidence estimates in various European
countries, which will correct previous inaccurate epidemio-
logical estimates of CF incidence that were confounded by
variation in the ability of primary health care to clinically
diagnose new cases of the disease [17].
Finally, we had previous estimates of death data and earlier
demographic analyses with which we could compare our results
[18–21]. The data reported here represent the most up to date
demographic data set and therefore differ numerically from our
earlier work focussing on Europe as a whole rather than
country-specific analyses [21]. In that analysis, we focussed on
the relative paucity of CF adults in countries whose gross
national product was very low relative to the old member states
of the EU. We also observed that the childhood demography of
CF in these countries was suggestive of under diagnosis and
premature childhood mortality given that the underlying CF
gene frequency was not different between the compared regions
of Europe [21].
To determine the demographics of CF across countries in
Europe, anonymised patient data from participating countries
were collected using Microsoft® Office Excel™. Initially, a
spreadsheet containing basic demographic data fields (compat-
ible with the US Cystic Fibrosis Foundation PortCF programme
definitions — www.portcf.org) was designed to aid interna-
tional comparison and research. Some countries used this form
of reporting. This initial requested data set was subsequently
modified by colleagues from the European CF Society (ECFS)
(www.ecfs.eu), whereby additional clinical data were added.
This updated spreadsheet was completed by other countries. A
few countries with existing CF Registries preferred to use their
own spreadsheet for providing the necessary demographic data.
Finally, some of the existing CF Registries had earlier provided
data to the ECFS and for four such countries, these were
obtained directly from the ECFS. Importantly, all of the utilised
spreadsheets used identical definitions for the demographic data
reported here.Lithuania 2004 95
Macedonia 2007 90
Moldova 2008 72
The Netherlands 2007 888
Portugal 2006 233
Romania 2006 197
Russia 2007 535
Serbia 2007 70
Slovakia 2006 491
Slovenia 2007 107
Sweden 2003 362
Turkey 2007 481
Ukraine 2006 96
United Kingdom 2005 8027
Europe 2003–8 29,0952.1.1. Data validation
The data definitions for the demographic variables were
similar for all countries and all data were verified by one data
manager (M. Fraser; Dundee, UK) who has over 30 years
experience in clinical data handling in the UK NHS. Each
country's data were inspected and the very small minority of
records where either month/year of birth or gender were missing
were discarded. Likewise, duplicate records were disregarded.
This did not affect the overall results as shown later. The
protocols used to validate the obtained data are detailed
elsewhere [14].2.1.2. Data definitions and nomenclature
The year of data collection was taken as the year in
which the youngest reported patient was born for each
country. We justify this on the basis that CF care improves
relatively slowly by incremental steps taking several decades
so that differences in the time of data collection between
various countries were unlikely to significantly impact the
interpretation of data. As shown in Table 1, this year varied
between 2003 and 2008. In our analyses, adjustments were
made for the different years of data collection where age-
related information was being reported. Thus, in the figures
showing patients under 18 or over 18 years old and in the 5-
year age distributions the relevant number of patients
per country was calculated before aggregating data into
“European totals”.
Importantly, it should be borne in mind that where numbers
are small for an individual country, the percentages reported in
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are allocated arbitrarily to one or other ‘bin category’ such as a
given age band in the age distribution or age at diagnosis. In
such cases, a different allocation of even a few patients can
alter the percentages reported. Thus, all country graphs should
be considered as estimates to the nearest 2% and the somewhat
artificial ‘bin boundaries’ should be viewed with this
cautionary note in mind. The convention applied here is that
the age of a patient is calculated from the date of birth, but
adjusted to the 1st of January of the year after the ‘year of data
collection’ shown in Table 1. Where an age range is shown,
this is called a ‘data bin’ and the upper ‘bin’ boundary should
be read as less than the numerical age value shown and the
lower boundary should read ‘equal to or greater than’ the
numerical value. For example: 0–5 years actually refers to
children of 0–b5 years who lie within a bin, and 5–10 years
means 5 or more years old etc. In the adult children split ratios
(pie charts), any person eighteen years or older is reported as
an adult. In the case of age at diagnosis, data are rounded to the
nearest whole month. Thus, a patient diagnosed at 1 week of
age until day 15 was reported as diagnosed at 0 months, while
a patient diagnosed at 3–4 weeks was reported as diagnosed at
1 month of age.
2.2. Deaths
29,095 patient records were included for their demographic
data, including 1128 (3.9%) patients (from 27 countries) who
had died. Some, but not all, countries provided information on
patients who had died. The graphs presented for Europe include
all patients. However, the age related graphs for each individual
country have had records for these patients removed to ensure
accuracy of comparison at a country level. At a European
level, no significant difference was observed in the 5-year
age distribution when the small numbers of deceased patients
were excluded compared with when these were included
(see Discussion). For one country the inclusion of deaths in
their data created a falsely high unknown value data bin. For
example, when the CFTR genotype of a dead patient was
unknown, it would appear that the percentage of unknown
genotypes was high. In fact, CFTR genotype data would have
been more useful if only living patients were used as the
denominator. Thus, the unknown columns reported need to be
treated with some caution, but we are confident that reporting
will improve in the future.
2.3. Exclusions and caveats
Only 66 (0.2%) of records (from 15 countries) were excluded
because either month/year of birth or gender data were missing.
The age at diagnosis was not provided for 210 patients (0.7%)
and was estimated from the date of CFTR genotyping. In
addition, a further 6 countries in Europe expressed their
willingness to participate, but due to delays in obtaining the
necessary local legal and ethical permissions or due to severe
local resource limitations, they have been unable to provide data
in time for this publication. Some countries outside Europe alsoexpressed an interest, but we were unable to include their data
due to a lack of resources. Simple clinical data were requested,
but on closer inspection had to be excluded from the analysis as
they were not comparable across countries. For example,
percent predicted lung function could not be used as different
countries used different reference equations to perform their
calculations. As the date at which lung function was recorded
was not requested, it was not possible to recalculate all raw lung
function values using a common equation. Likewise, it was not
known whether a country had provided the ‘best’ lung function
value in the year, the ‘average’, or simply the ‘reading on the
day’.
2.4. Anonymisation and analyses
For the merged European data set, all patients were further
anonymised in Dundee by creating a country and clinic code in
order to avoid the possibility of a patient being identified in the
European data set from a combination of factors. This was
particularly the case for countries with small numbers of
patients reflective of a more limited CFTR genotype distribu-
tion, the presence of a frequent founder mutation(-s) specific for
a given population or the failure to recognise most patients with
the disease in their health care setting. All analyses were carried
out using Microsoft® Office Excel and Microsoft® Office
Access.
2.5. Ethical and legal issues
Prior to requesting data from any of the participating
countries, compliance requirements were checked with the
Data Protection Directive 95/46/EC (http://ec.europa.eu/justi-
ce_home/fsj/privacy/law/index_en.htm) and relevant Member
State Data Protection laws and ethics rules (data not shown).
Following advice from the UK Data Protection Officer
(Europe), a sample Patient Information Sheet and sample
Consent Form were drafted and approval obtained from the
EuroCareCF legal and ethical experts (Workpackage 8, H.
Nys, K.U. Leuven, Leuven, Belgium). Next, a set of
procedures was circulated for each country to ensure
compliance with their own national laws and ethical require-
ments. Both sets of documents are also available on line [21]
as web appendices, but are reproduced here with permission
from the Lancet for convenience. These procedures took into
account the design of any ultimate software package and its
associated protocols. These protocol issues were discussed at
meetings of users set up during the course of the project. In
order to protect the anonymity of patients in some of the
countries with small numbers of patients reported and to
comply with local laws and ethics procedures, all countries in
the country-specific sections of this report are identified only
by a randomly allocated confidential country code, which is
known only to each country representative. However, each
country coordinator was asked for their permission to declare
their total patient numbers as shown in Table 1. These ethical,
legal and consent procedures have been adopted by the ECFS
and will serve as a basis for procedures within the new
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development (http://qa.ecfs.eu/projects/ecfs-patient-registry/
introduction).
3. Results
The participating countries and their patient numbers are
shown in Table 1. While every effort has been made to include
information from as many patients as possible, the data reported
here do not necessarily include all patients in each country. In
less than 5 countries, for example, only data from one large
centre were available, but generally coverage exceeds 50%. At
the time of writing this paper in late 2009, many of these
countries have updated their patient numbers for inclusion in the
newly developed ECFR.
We began our analysis by focussing on the sex and age
distributions where and adult is defined as being 18 or greater
years of age. We recognised that the age at which a child legally
becomes an adult varies across Europe. For example, in some
countries, such as the UK, CF ‘adults’ transfer from children's
clinics at earlier ages (around 16 years), but we did not collect
these data and figures for adults should be considered as
minimum values (see Methods).
3.1. Demographic profile
The data demonstrate that CF adults (12,616 patients) and
CF children (16,479 patients) have not yet reached parity across
Europe as a whole and there are approximately 4 CF children
for every 3 CF adults (57% versus 43%, respectively) in our
aggregated CF centres (29,095 total patients). While it is
recognised that, at birth, there exists a slight excess of male overFig. 1. Age distribution of CF patients: the bar graph shows patients in 5-year age gro
than 35 years old at the year of reporting are aggregated in the last column. The pe
numbers of patients in these 5-year age groups, the percentages of which are shown
Methods.female births in the non-CF population (around 1.1 males for
every female), that male excess in non-CF babies is offset by a
higher male mortality in childhood thus restoring the balance by
reproductive age. However, for CF children a clear male
preponderance persists and this is even reflected at all ages such
that 53% (15,302) are male from 29,095 patients. In summary,
in CF, males outnumber females and children outnumber adults
in Europe.
We were also interested to examine the age profile of CF
patients while recognising that only a small minority of
countries were screening for CF at birth at the time the data
were collected. Hence (Fig. 1), childhood and adult cases were
divided into five year age bands (see Methods for age boundary
definitions). We were expecting our observed relative paucity of
diagnoses in very young children (since they would not yet have
been clinically ascertained) in the absence of Europe-wide
neonatal CF screening when compared to those found to be
already at school age at the time of data collection. Thus, Fig. 1
shows the expected pattern of patients by age in five year age
bands. To a first approximation 1500 CF pre-school children
were ‘missing’ since only 3524 children were of pre-school age
compared to the expected number of about 5000. Thus, there
remain many undiagnosed young CF children in Europe, some
of whom may well have already died because the height of the
first bar of pre-school age children is lower than that for older
children. In early adult life there is also the expected sharp
decrease of the 25–30 year old group, which more than halves
in number between 30 and 35 years of age. This rate of change
per decade for Europe as a whole is analysed elsewhere in detail
[21]. That analysis showed a significantly greater decline in
patient numbers with each succeeding decade in patients
reported from the Eastern parts of Europe relative to the moreups as a percentage of total patients (29,095) in the data set. All patients greater
rcentages are rounded hereafter unless otherwise stated. The table shows actual
in the bar graph ordinate. For the allocation of patient ages into each bin, see
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‘missing’ adult patients is unknown, but the pattern of decline
fits with the expected age of maximum mortality [7]. This older
group size disparity most likely reflects differential outcome
consequences of inadequate childhood nutrition from an earlier
era of unavailability of acid-resistant pancreatic enzyme
substitution in the early part of the nineteen eighties in some
countries.
3.2. Gender issues
Having observed a “female disadvantage”, we focussed on
the percentage of males and females by age (Fig. 2) and found
that overall, males significantly outnumber females and that this
trend further increases in adults. In order to determine the age of
onset of the “adult increase”, we plotted the age/gender
distribution data in five year bands as before to reveal the
underlying trend (Fig. 3). The post pubertal onset of the male
female ratio imbalance is clear whereby the boys outnumber the
girls by one percent point per 5-year age bin and this disparity
persists after puberty consistent with the known decreased
survival of females in some countries. However, we also note
that the excess number of young CF males is consistent across
age bins, but becomes even more pronounced as the analysed
age increases. The gap between young boys and girls is less than
one percentage point per age bin, but the cumulative difference
is a full 4 percentage points and is highly significant using a test
of proportions (pb0.001). Thus, even in childhood there exists
a relative paucity of girls (see Discussion).
3.3. Genotypes
Next, we determined the spread of CFTR genotypes across
Europe (Fig. 4) using the most common CFmutation as a general
indicator for ‘PI-inducingmutations’ genotype distributions: 46%
of all cases were homozygous for the widely prevalent PIFig. 2. Males outnumber females at all ages. Gender split as a percentage (rounde
percentage of all patients who are more than or equal to 18 years old (12,616, right)
proportions the differences are highly significant (pb0.003) with an estimate of thephenotype p.Phe508del mutation, p.Phe508del in compound
heterozygosity with another non-p.Phe508del CF-causing muta-
tion accounted for 39% and the minority with no p.Phe508del on
either allele comprised the remaining 14%. It is important to note
that this distribution is drawn from only ~26,000 patients and not
from the entire 29,095 patient data set. The missing genetic data
are highlighted in the legend Fig. 4.
3.4. Age at diagnosis
Next, we determined the age at diagnosis and tested the
hypothesis that the CFTR genotype would affect the age at
diagnosis (Fig. 5). These data show that many patients continue
to be diagnosed beyond infancy as expected consistent with the
fact that neonatal screening was not widespread across Europe
at the time of data collection. Additionally, Fig. 5 shows that
few patients (less than 1%) who are homozygous for the p.
Phe508del mutation are diagnosed in early adulthood. The
remainder are diagnosed throughout childhood and later in adult
life (Fig. 6) reflecting the heterogeneity of the underlying CFTR
mutation distribution and the severity of pancreatic disease.
Thus, the key advantage of studying the homozygous “p.
Phe508del disease” is that outcome reflects childhood care in
more than 95% of cases.
3.5. Relevance to European CF outcomes
A key ‘Governmental’ objective of the EuroCareCF project
was to empower each country representative (who might not be
medically trained) with the tools to compare their own data with
those of Europe as a whole in a simple format easily understood
by non medical staff and/or policy makers. However, it was
agreed at the outset that countries should not be identified
without their consent in order to protect their anonymity. The
latter problem was acute in those countries with a handful of
patients (such as Iceland) who could potentially be identified byd up) of all patients who are less than 18 years old (16,479, left chart) or as a
. The table shows actual numbers of patients in these categories. Using a test of
true value for females residing between 47 and 49%.
Fig. 3. Onset of male excess: the bar graph shows males and females in 5-year age groups as a (rounded up) percentage of total patients (29,095) in the data set. All
patients greater than 35 years old at the year of reporting are aggregated in the last column. The table shows actual numbers of males and females in these 5-year age
groups, the percentages of which are shown in the bar graph rounded to the nearest integer which explains the apparent differences in bar height.
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chose 70 patients as an arbitrary cut-off below which numbers
of patients would not be specified per country to avoid any
potential breach of anonymity.
Nevertheless, in order to maintain data utility for a given
country, we allocated a secret country code which remainsFig. 4. Genotypes: the pie chart shows patients in the genotype categories “p.Phe5
percentage of all patients where genotype was reported (26,118). The table shows act
figures. The pie chart does not show patients where genotype was not reported (297confidential to that country and on that basis, in Appendices 4
and 5 we reproduce key comparative Figures for Europe as a
whole, but now reformatted to facilitate easy cross comparison
at an individual country level (Appendix 5). Comparison of
these two Appendices illustrates the substantial diversity of
country-specific demographics with the caveat that these should08del/p.Phe508del”, “p.Phe508del/other” and “other/other” as a (rounded up)
ual numbers of patients in these categories which differ from the totals in earlier
7), 10% percent of total number of patients in the data set (29,095).
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enough to exclude random errors arising from small data set
variations.
The power of our simple demographic and gender based
approach is reflected by an example (Fig. 7) which at first
glance (upper graph) looks very similar to Europe as a whole,
but upon further inspection of its underlying gender ratio
reveals a marked difference in prevalence for young males
versus females (lower graph). Other disparities between
countries are presented in the Appendices, referenced against
Europe as a whole and are intended for use by participants of the
project to illustrate to their respective funding bodies and/or
policy makers how a comparison of their own country data
might provide evidence to improve their resource allocation for
CF care.
4. Discussion
EuroCareCF was a comprehensive pan-European effort
running from 2006 to 2009 consisting of a number of projects
(Workpackages described on the web site www.eurocarecf.eu)
aimed at enhancing complex CF research and care across the
EU. Our second Workpackage focussed on registry issues and
its main outcomes are reported here. Our primary purpose was
to measure CF demography across European countries. This
ambition required a legal framework based on sound ethical
principles that did not violate data protection laws that are
applied differently in each country (see Appendices 1–3 for the
forms used for consent as examples, reproduced from Lancet
with permission). In this way, we could take the initial, but
critical data survey step using a restricted, but high quality, data
set. Our hypothesis was that only then could we contemplate
making the necessary incremental advances in the depth of
comparative data coverage based on our earlier experience that
identified the key problems associated with an international
comparison using clinical data [5,19]. Our secondary purpose
was to present our results in an easy to digest format for a non-
medical audience where an individual country could compare
how well they were performing against Europe as a whole.
Hence, the comparative data set in Appendices 4 and 5 coupled
to the subset of archetypal graphs reported in the main results
section can be combined to illustrate the key differences in
demographic profile for 29,095 patients in Europe against
which each participating country can easily compare their own
profile. Thus, we believe we have set a standard against which
future improvements can be measured, thereby meeting our
major objective within Workpackage 2 of the EuroCareCF
project. We have excluded any reference to the aims of otherFig. 5. p.Phe508del/p.Phe508del genotype is largely of childhood presentation: the u
total patients (29,095). Patients diagnosed later than 50 years old are aggregated int
reported. The percentages are rounded (e.g. 0% indicates less than 0.5%). The upp
percentages of which are shown in the bar graph. Many diagnoses occur after the new
above the age of 15 years which is consistent with the recognised natural history of C
p.Phe508del patients grouped by age at diagnosis as rounded percentages of all p.Phe
p.Phe508del/p.Phe508del patients in the groups. This form of CF hardly ever prese
without this p.Phe508del on either chromosome who, in direct contrast to the commWorkpackages as these will be covered in later reports
published in a separate supplement to the Journal of Cystic
Fibrosis.
4.1. How should these demographic CF data be interpreted?
The relative paucity CF patients in some countries reported
here cannot be attributed to a lower population prevalence of the
defective CFTR alleles when referenced against the known
geographic distribution of CFTR mutations in Europe [17] and/
or when assessed by thorough analysis of CF prevalence in
Europe [20]. In a separate paper [21], we have highlighted
related issues of context by analysing a less complete version of
this data set (from 2008) but there, we used the gross national
product of groups of countries as a divisor. In that study, we
found significantly poorer demographic outcomes in aggregates
of those countries who were not members of the EU in 2003 and
suggested that resource allocation may be a key issue for early
clinical diagnosis, treatment and hence, CF outcomes for a
given health care system [21]. As in this study, to keep within
our consent, we did not identify any particular country.
However, for the current paper, we additionally wrote to each
country to ask them for permission to report the raw numbers in
Table 1. Crucially, from our new analysis reported here, it is
apparent that some countries' demographics are demonstrably
failing to reach the European average, which is admittedly
skewed by an overrepresentation of patient numbers from
economically advantaged nations in the west of Europe (~75%
of the total). As might be expected, this enhanced ability to
collect data from most CF patients in wealthy countries reflects
better coverage based on the maturity of their CF registries, their
earlier establishment of nation-wide CF centres and the
consequent better survival of CF patients into adulthood. We
suggest that the country-specific data outputs shown in
Appendix 5, particularly focussing on children under the age
of 15, when combined with our Europe wide analysis [21] and
comparisons in Appendix 4, show that much could be done to
help improve the health status of CF patients in certain
European countries relative to their more affluent neighbours.
We have exercised considerable caution in data presentation
because we were anxious to avoid any simplistic ‘league table’
format as we and others have previously found this to stifle
progress in interpretation unless due care be taken to counter the
effects of random variation [22]. In EuroCareCF, because each
country knows their own secret country code, but each is
unaware of the coded data from their peers, they can in the first
instance, discuss, update and add to the depth of their data
internally (which many have already done, not shown) beforepper bar graph shows all patients grouped by age at diagnosis as a percentage of
o one column. The last column shows patients where age at diagnosis was not
er table shows actual numbers of patients in the age at diagnosis groups, the
proposed gold standard at 2 months (see Discussion). Only 5% of cases present
F as a childhood disease. The lower bar graph shows the equivalent p.Phe508del/
508del/p.Phe508del patients (12,129). The lower table shows actual numbers of
nts in adult life. The next figure shows that the reverse is the case for patients
on genotype, form the majority of adult diagnoses.
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approach may seem to be needlessly restrictive, whenever
data are presented for the first time at a country level, ourexperience in the UK and elsewhere shows that it is an
important confidence building measure for such countries to be
able to discuss their own data frankly with their own health care
Fig. 6. Non-p.Phe508del on either chromosome and adult diagnoses: the bar graph shows patients in the two genotype categories, p.Phe508del/p.Phe508del versus the
rest comprising the sum of heterozygotes for p.Phe508del with another disease allele, other/other and unknown genotypes. Patients are grouped by age at diagnosis,
split into the two groups, as a percentage of all patients (29,095). Patients diagnosed later than 50 years old are aggregated into one column. The last column shows
patients where age at diagnosis was not reported. The percentages are rounded (e.g. 0% indicates less than 0.5%). The table shows actual numbers of p.Phe508del/p.
Phe508del and non-p.Phe508del/p.Phe508del (other/other) patients. Adult CF diagnoses almost never bear a p.Phe508del allele in a homozygote state.
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to public analysis at a European and/or national “governmental”
level. This caveat does not apply to those countries with mature
registry data sets spanning decades with their attendant
coverage of about 70–80% of CF cases. They have already
begun these discussions in recent years in an effort to improve
resource allocation or quality management as is the case in
Germany, for example. Earlier, we applied a similar confiden-
tial approach across CF centres in the UK [14,15,19] and
recently, in Scotland, CF Centre Directors have agreed to share
their local secret codes to internally audit their outcomes.
However, not every country representative agreed with our
approach and one CF parent representative expressed deep
reservations. She informed us that her own government would
‘take no notice of this paper’ unless they were ‘named and
shamed’ into action in the full glare of the EU Commission. It
might be that some country representatives will place their own
data in the public domain in order to help persuade their ownauthorities that something must be done to improve their
demographic profile. However, this is not a matter for us as it
lies outside of our remit and consent. The main concern on our
side is the uncertainty about the depth of coverage for a given
country with an apparently ‘poorer’ outcome. However, there
are some findings that cannot easily be dismissed as either bias
due to lower national or regional rate/proportionality of case
ascertainment or an artefact due to population-based variations
in CF carrier frequency, as discussed elsewhere [21].
4.2. Is there a wider message for EU Health expenditure in
rare diseases?
4.2.1. Setting demographic standards for CF outcomes
Even if the outcome data reported here are indeed biased
in some countries, today's CF patients should nevertheless
have a mortality of less than 5% by the time they reach
15 years of age when cared for in a relatively affluent country
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Fig. 7. Gender and outcome: comparison of the overall age profile in the upper graph with the data in Fig. 1 suggests that this country has no difference when compared
to Europe as a whole but the sex ratios tell a different story with an unexplained paucity of pre-pubertal girls that requires further explanation (see text in Discussion
section about delayed diagnosis in females).
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as complete as possible in terms of avoiding ascertainment
bias, this sets an international benchmark for completeness and
we can be confident in using them as a target measure. The
critical pioneering vision of Professor John Dodge (UK) is
acknowledged in this respect in setting up the underlying
methodology from the 1960s. Thus, with respect to CF
outcome, we should observe a stable (i.e. within 5%) number
of children in 5-year age bins between 5–10 years and 10–
15 years. In our view, this is a measurable standard for all
countries to aspire to in the next phase of this work under the
auspices of the ECFS.
These emergent ideas relate to a third EuroCareCF ‘aim’which
only became apparent from repeated questions posed to us by
many different organisations (outside of CF care) responsible for
other rare diseases (e.g. Eurordis; www.eurordis.org or Orphanet;
www.orpha.net), including representatives of the secretariats of
different European governments during the process which led to
the adoption of the “EUCouncil Recommendation on an action in
the field of rare diseases (2009/C151/02)” (http://eur-lex.europa.
eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF) in June 2009. Their frustration lies in developing
robust methods to remotely assess disparities in diagnosis and
care for rare diseases across Europe without the confounding
factor of poor coverage in rare diseases casting doubt on the
conclusions. Their interest lies in measuring the degree to
which taxpayer spend translates into better health in the area of
rare diseases at Member State and/or EU levels. Furthermore, at
the EU level, knowledge of measurable demographic variables,
with CF being a useful example because of its random
occurrence, various EC directorates (such as DG Sanco)
could foster a critical evaluative process by Community level
programmes, albeit respecting the principle of national
subsidiarity with regard to health care provision. Moreover,
since the USA currently is also embarking on Universal Health
Care, similar considerations may well apply to health
disparities in the wealthiest country in the world. In our CF
presentation at the EU parliament in 2009 (at the invitation of
the patient organisation, CF Europe — http://www.cfww.org/
cfe/), we pointed out to twenty members of Parliament or their
representatives, that our CF “registry paradigm” could provide
an answer of broader applicability to rare disease in general by
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country may wish to “officially” compare their data with their
neighbours and report differences to their respective members
of the EU Parliament. These issues received substantial
attention at the 5th European Conference on Rare Disease in
Krakow — Poland (http://www.rare-diseases.eu/2010/) and it
has been acknowledged that CF serves as a model for other rare
diseases in this regard.
4.2.2. What should be done across Europe?
A CF outcome measure based on cross-sectional demo-
graphics could enable the EU Commission to compare health
care across Europe thus measuring multiple modalities in one
step should the numbers of CF patients decline across 5-year
age bins as children age. We therefore propose a self-
referencing simple measure (well within the compass of
any CF Centre or the simplest CF disease registry) that
aggregates the ability of a country's health care system to firstly
diagnose pancreatic insufficient CF (ascertainment of failure to
thrive), and secondly demonstrate an ability to treat it
effectively in childhood (delivery). We put forward this simple
demographic measure because CF arises both randomly and
unexpectedly with a high enough population frequency of its
carriers coupled to a potential lethality in CF-affected babies if
missed. Thus, we consider such CF outcome as part of a broader
reality — namely, a measure of the ability of any given health
care system to cope with an unexpectedly ill child presenting
with multiple organ failures in a targeted and effective manner,
see outcomes after CF-related diabetes (CFRD) as a critical
example [23]. Hence, we consider survival into late childhood
in CF to be a marker of the degree of fitness for purpose of any
health care system that claims to care for unexpectedly sick
children with a chronic multi-system disease; in this instance a
disease that is among the commonest of inherited rare diseases.
Our country-specific data demonstrate that many countries in
Europe are not apparently matching their CF outcomes against
the ‘best’, defined here as outcomes in well resourced and long
standing members of the EU who have published their own
outcomes through their own CF patient organisations with
robust external validation in one instance [7], i.e. in order to
ensure that the data reported are reliable. Such outcomes from
relatively economically advanced nations are generally in line
with the European pattern as a whole. Recently, Mastella and
colleagues [24] compared CF outcomes across the globe and
they make a key observation. They comment that properly
targeted and CF-specific high calorie nutrition, which is
relatively inexpensive for any EU member state, should be
the first step towards improving CF outcome. They cite the
recent dramatic effects of improving caloric intake in Quebec
with corresponding enhanced survival within two decades of
introduction. In our view, this should be a critical early step in
the next phase of CF data gathering across Europe to try and
determine whether poor childhood nutrition can explain why
the demographic patterns are so different in some countries.
When this idea is coupled to newborn screening for CF (which
was not generally prevalent in Europe at the time we undertook
this work and may not be affordable in some countries), whichpermits an early introduction of a suitable high calorie diet and
replacement pancreatic enzyme therapy, then it might be
expected that CF survival will dramatically accelerate using
relatively simple measures whose effects are easily measurable,
as discussed elsewhere [21].
4.3. Why is there a female disadvantage in CF?
When considering survival, female gender and its attendant
poor CF outcome is also clearly an issue to consider [23].
Disadvantaged female survival is a complex area with an
amalgam of effects causing the disparity between genders (inter
alia, worse outcomes after puberty for females with particular
reference to CF-related diabetes, the different effects of oestro-
gens versus androgens on CFTR, the unexpected presence of
CFTR in the hypothalamus and its associated effects on hormone
secretion, delayed diagnosis in females in some, but not all parts
of the world). These matters, while of great significance to CF
research, lie outside the scope of our remit. They combine to
create an easily measurable ‘gender ratio metric’ of relevance to
gauge CF outcome because they are amenable to therapy and
crucially, might also reflect the response of care teams to gender
issues (a critical country example is shown in Fig. 7). Therefore,
another future outcome standard for governments might be the
relative stability of the numbers of males versus females within
less than one percentage point of one another over childhood.
These will be matters for the new ECFS European CF Registry,
respective national CF patient support groups, their trans-national
organisation via activities of CF Europe (www.cfww.org/cfe),
and for the ECFS Board.
4.3.1. Is the observed male excess a reflection of distorted
gender-related segregation of mutated CF alleles
(or “meiotic drive”)?
Kitzis et al. [25] refuted the previously suggested preferential
transmission of mutated CF alleles through fathers, but
intriguingly found a statistically significantly increased number
of obligate CF carriers among male siblings, together with a
decrease of female carrier siblings, in a large collaborative study
analysing European and North-American CF patients with
regard to the expected Mendelian pattern expressed by the “2:1”
carrier/patient ratio. Although subsequent single sperm-based
molecular genetic typing within a sizeable cohort of sperm
derived from one p.Phe508del carrier did not find significant
differences between the number of p.Phe508del-X chromosome
and p.Phe508del-Y chromosome bearing sperm [26], our
observation of male excess in childhood in Western European
cohorts associated with low early childhood CF mortality rates
requires further exploration of this intriguing issue in a larger
cohort of p.Phe508del carriers.
4.4. Recognition of sources of bias and their potential impact
on the project
4.4.1. Data deficits
In any exercise of this magnitude there are unavoidable
limitations. Unlike a highly prevalent, but potentially life-long
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normal children at some time in their lives, the relative paucity
of CF suffers for a given hospital or country [20] creates the
problem of incomplete case ascertainment. This is made worse
by the fact that the clinical diagnosis of CF is not as straight
forward as for instance in the case of asthma. Thus, we
recognise that the data reported here reflect poor coverage of the
CF population for a given country which is only to be expected
given differences in history and resources in different parts of
Europe. In our previous experience in a well resourced Western
European setting, we were only able to improve data capture
from 40% to over 70% over the course of ten years and our
efforts have been reviewed by others elsewhere [24]. These
reviewers note that an incremental approach to data gathering
has been adopted by many countries, also over many decades
(North America, France, UK, Germany and others). Thus, the
data reported here should be viewed only as a first step from
which our (currently unknown coverage for many participants)
should improve for those countries without a recognised data
gathering infrastructure. Setting each individual country a target
of around 70% coverage seems a reasonable five year goal.
4.4.2. Country deficits
There was a necessity to make an initial list of established
European CF centres aggregated into Table 1 whose identities
were ascertained through surveys of national and international
CF patient organisations and from members of the ECFS.
Importantly, one of us (MM) was able to utlilise his long
standing contacts throughout Central and Eastern Europe based
on his previous coordination of population genetic studies in CF
[17] making us believe we have as broad a coverage as might be
reasonably expected. Despite these efforts, some countries
could not supply data in time to meet our tight deadlines.
Overall, we recognised two sorts of bias affecting the reported
prevalence of CF children and adults in our study. Although
both biases result from undiagnosed CF cases, given the fact
that many of the presenting features of CF are of general nature
(diarrhoea, pneumonia, failure to thrive, prolonged jaundice,
or heat shock in warm climate being typical examples),
they nevertheless operate at different ages within the CF
severity spectrum. In some paediatric CF clinics, such
patients may not have been identified because as many as 1 in
5 CF-affected babies might have already died unrecognised in
the absence of neonatal screening. These missed cases are
often labelled as having died from pneumonia or gastroenteritis
by those untrained in CF disease [18]. Such under-ascertain-
ment in childhood also pertains at the opposite end of the
clinical severity spectrum where the mild CF cases often go
unrecognised throughout childhood and are usually only
sporadically clinically recognised later in adulthood. This latter
factor falsely elevates survival estimates when new adult
entrants replace dying childhood cases. In addition, the issue of
a delay in the diagnosis of CF in females might explain our
failure to find the expected number of females (see above and
Fig. 7). Thus, at the outset we recognised that our reported
demographic data must be considered as the minimum
prevalence.4.5. Technical issues relating to cohorts
A second caveat to our conclusions is that the year of data
collection for the participating countries varied between 2003
and 2008. Although this was not optimal, we felt that as this was
the first time that a large number of European countries had
collected and pooled their data, this range of years offered the
greatest flexibility to participating countries to provide the
maximum amount of data that they were realistically able to
gather within the limited duration of the EuroCareCF project.
Further, even some of the countries with existing registries were
able to provide maximum data for a pre-specified year only,
often in the earlier part of the period 2003–2008. Because the
demographic profile for Europe would not be expected to vary
greatly within the 6-year period studied and because CF
outcomes such as improved survival evolve only by decades of
practice change [7], our chosen range of years was considered
the most practical for the demographic analyses reported here.
The maximum likely discrepancy in outcomes measured as
survival would have been in the range of two years median
survival. To determine the magnitude of this effect, we also
tested whether deaths might affect our analyses for Europe
because we included all patients who had been identified as
deceased within the total reported (n=29,095). To confirm that
this death inclusion did not significantly affect the final figures
if the deceased patients had been omitted, we recalculated the
European 5-year age distribution removing deaths (n=27,967).
Fig. 8 compares the two sets of figures and substantiates the
particularly high robustness of our data.
4.6. Country-specific reports
4.6.1. Matters for national authorities under EU health
care-related “subsidiarity” rules
In health care matters, subsidiarity implies that Member
States are responsible for their own health outcomes. Many
countries reported here manifest delayed ‘ages at diagnosis’ as
shown in the country-specific data to be found in the
Appendices. Even if a correct CF diagnosis is made, recent
data suggest that an inability to make an early enough
diagnosis (enabling prompt and targeted therapy in CF) may
adversely influence surrogate markers of a poor prognosis in
childhood CF [27]. Such ‘diagnosis-delayed’ children may
well survive into adulthood, but suffer from markedly
impaired overall clinical status, thereby increasing treatment
and management costs needlessly. Indeed, Phillipp M. Farrell
when commenting on the idea that early diagnosis is
prognostically important suggests that the new gold standard
to improve outcome should be initiation of first line therapy by
two months of age (rather than the current three months)
following the recent introduction of various CF newborn
screening schemes in the majority of US states [28].
We adjusted our ‘age at presentation’ graphs reported here
accordingly and found that many CF patients continue to be
diagnosed very late in childhood. This factor could also have
introduced a bias into our demographic findings on the profile
of CF at different ages because some CF-affected children not
Fig. 8. Accounting for deaths: deaths do not influence the overall demographic profile.
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Thus, we were expecting a lower number of “older” adults
versus children with CF in some countries. However, failure to
find enough older CF adults in a given country might not solely
be due to earlier childhood death. Another potential source of
bias might occur because adult CF centres might not be
established in a given country leading to patient dispersal to
physicians outside CF after childhood was complete. This is
offset by the factor that in some instances, paediatric clinics
continue to treat their older patients because no specialist adult
care is available. After all, even in a well resourced country like
the UK, adult CF care is a relatively recent development as a
result of patient pressure on Governments that followed
increased childhood survival. In some countries such as
Scotland, adult care is funded centrally by top slicing NHS
budgets, but this is far from universal. Thus, a failure to find
enough CF adults reported from some countries might also
reflect gross under-reporting as their care might be dispersed to
general pulmologists and/or gastroenterologists with limited CF
expertise or indeed, they may be sent back to primary care to
manage their own disease. Based on the analyses reported by
Britton and co-workers reported above [18], the expected net
effect of these potential biases on our expected demography was
such that there would likely be a gap of at least 20% between the
expected number of CF cases from the known mutated CFTR
allele prevalence in a given country and the much lower actual
number of clinically diagnosed CF cases reported from the
specialist clinics within our survey.
4.7. Next steps
4.7.1. All data fields are not of equal value for
outcome determination
Others have led the way in data field discrimination. For
example, Marshall and colleagues published a model [29] that
might be predictive of survival in a US setting and comment that
not all data items in a registry are prognostic for survival. These
authors suggest that a focus be placed on age, sex, FEV1, weight-
for-age as a Z score, pancreatic status, diabetes mellitus (CFRD)and Staphylococcus or Burkholderia chronic bronchial colonisa-
tion status. However, this approach is not the only one available
and O'Conner and colleagues from Canada take a slightly
different view [30] focussing on age, gender, age at diagnosis,
sweat sodium concentrations, ethnic origin, symptoms at
diagnosis and the distribution of CFTR genotypes. Although the
model developed byMarshall and colleagues [29] was developed
for the purpose of the Cystic Fibrosis Foundation and the specifics
of the US health care, it remains to be properly substantiated how
data field discrimination might be applied in Europe with its
diverse national and/or regional health care approaches. The most
appropriate variables for collection are currently under discussion
within the European CF Registry Working Group that succeeded
EuroCareCF initiative. In the view of the authors of the current
paper, gender, CFTR genotype and age at diagnosis are critical
issues because their intrinsic variability may also help us to
understand CF natural history at a country level.
4.7.2. Exit strategy
The EuroCareCF project was of a fixed duration, ending in
June 2009.At the project outset, it was therefore important to have
a clear exit approach inmind to ensure continuity. Our report does
not address clinical data, which are being handled by the ECFS
separately although clinical data were collected where possible on
a pilot basis to ascertain likely difficulties (not shown). Once all
countries start to use the standard software being implemented for
use across Europe by the ECFS, or they are able to standardise
their data definitions to a common agreed European basis
(underway through activities of M. Stern, Tübingen, Germany),
such obstacles will be more easily overcome. The ECFS with
whomEuroCareCF has worked closely andwho are committed to
continuing the European CF Registry after the end of the
EuroCareCF project are currently addressing these issues (http://
www.ecfs.eu/projects/ecfs-patient-registry/intro).
In conclusion, CF demographics vary greatly across
Europe. The reasons need to be examined critically at a
country level in order to set standards for improvement. We
urge the European Commission and all European Member
State Governments whether inside or outside the EU to act
S21G. Mehta et al. / Journal of Cystic Fibrosis 9 (2010) S5–S21swiftly. We also ask these governments to evaluate the use of
outcome in childhood as a surrogate marker for the ability of
their own general health care systems to deliver at the citizen
level in a life-limiting inherited disease that occurs randomly
and crucially, is lethal unless treated promptly.Conflict of interest statement
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